Structural and Phylogenetic Studies with MjTX-I Reveal a Multi-Oligomeric Toxin - a Novel Feature in Lys49-PLA2s Protein Class

The mortality caused by snakebites is more damaging than many tropical diseases, such as dengue haemorrhagic fever, cholera, leishmaniasis, schistosomiasis and Chagas disease. For this reason, snakebite envenoming adversely affects health services of tropical and subtropical countries and is recognized as a neglected disease by the World Health Organization. One of the main components of snake venoms is the Lys49-phospholipases A2, which is catalytically inactive but possesses other toxic and pharmacological activities. Preliminary studies with MjTX-I from Bothrops moojeni snake venom revealed intriguing new structural and functional characteristics compared to other bothropic Lys49-PLA2s. We present in this article a comprehensive study with MjTX-I using several techniques, including crystallography, small angle X-ray scattering, analytical size-exclusion chromatography, dynamic light scattering, myographic studies, bioinformatics and molecular phylogenetic analyses.Based in all these experiments we demonstrated that MjTX-I is probably a unique Lys49-PLA2, which may adopt different oligomeric forms depending on the physical-chemical environment. Furthermore, we showed that its myotoxic activity is dramatically low compared to other Lys49-PLA2s, probably due to the novel oligomeric conformations and important mutations in the C-terminal region of the protein. The phylogenetic analysis also showed that this toxin is clearly distinct from other bothropic Lys49-PLA2s, in conformity with the peculiar oligomeric characteristics of MjTX-I and possible emergence of new functionalities inresponse to environmental changes and adaptation to new preys. © 2013 Salvador et al.

Ação de compostos vegetais sobra a atividade da Piratoxina-I, isolada do veneno de Bothrops pirajai, em preparação neuromuscular de camundongos

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Eicosanóides no aumento de permeabilidade vascular e componente celular da inflamação aguda em Piaractus mesopotamicus

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Estudos conformocionais de diversas proteínas em solução utilizando a técnica de espalhamento de raios-X à baixo ângulo-saxs

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Estudos estruturais experimentais e teóricos com proteínas do veneno da serpente Bothrops jararacussu

Pós-graduação em Ciências Biológicas (Genética) - IBB

Avaliação das atividades antinociceptiva e anti-inflamatória do extrato hidroetanólico de partes aéreas de Portulaca pilosa L. (Portulacaceae)

Este estudo investigou a toxicidade aguda oral, o efeito antinociceptivo em modelos de nocicepção química e térmica, bem como a atividade anti-inflamatória em modelos de carragenina e óleo de cróton do extrato hidroetanólico de partes aéreas de Portulaca pilosa (EHEPp). Identificou também alguns possíveis mecanismos envolvidos na antinocicepção do extrato, além dos seus efeitos sobre o sistema nervoso central de ratos. No teste de toxicidade aguda oral, o tratamento com EHEPp (2000 mg/kg) não causou óbitos. No teste de contorções abdominais induzidas por ácido acético, o EHEPp (100, 200, 400 e 600 mg/kg), por via oral (v.o.), reduziu significantemente o número de contorções em 18.18, 33.25, 47.27, 65.81 e 73.94%, respectivamente. No teste da placa quente, o tratamento com EHEPp (200, 400 e 600 mg/kg, v.o.) não alterou a latência ao estímulo térmico de 50 ± 0,5 ºC. No teste da formalina, o tratamento com EHEPp (200,400 e 600mg/kg, v.o.) reduziu de maneira significativa o tempo de lambida nas fases neurogênica (1ª fase) em 38.79, 60.61 e 75.18 %, e inflamatória (2ª fase) em 49.23, 53.03 e 87.53 %, respectivamente. A administração prévia de naloxona reverteu, significativamente, o efeito do EHEPp (600 mg/kg, v.o.) em ambas as fases do teste da formalina. O pré-tratamento com o L-NAME e azul de metileno reverteu o efeito do EHEPp (600 mg/kg, v.o.) de maneira significante em ambas as fases do teste da formalina. O pré-tratamento com o fármaco glibenclamida também reverteu de maneira significativa o efeito do EHEPp (600 mg/kg, v.o.) em ambas as fases do teste da formalina. O EHEPp, na dose 600 mg/kg, v.o., não afetou a atividade locomotora dos ratos submetidos ao teste do campo aberto. No teste de edema de pata induzido por carragenina e edema de orelha induzido pelo óleo cróton, o EHEPp (400 e 600 mg/kg, v.o.) não inibiu a formação de edema de maneira significante em ambos os testes. Os resultados deste estudo mostraram que o HEEPp, oralmente, apresentou baixa toxicidade e sua atuação antinociceptiva observada na fase neurogênica pode envolver interações periféricas com receptores opióides e ativação da via NO/GCs/GMPc/ K_ATP. Já a atividade antinociceptiva observada na fase inflamatória parece não depender de inibição da via bioquímica fosfolipase A2/ciclo-oxigenases, mas de interações periféricas com receptores opióides e com a via NO/GCs/GMPc/K_ATP.

An Evaluation of 3-Rhamnosylquercetin, a Glycosylated Form of Quercetin, against the Myotoxic and Edematogenic Effects of sPLA(2) from Crotalus durissus terrificus

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Estudos estruturais e cristalização de complexos formados entre toxinas botrópicas e inibidores vegetais

This research presents a study of structural complexes formed between the bothropstoxin BthTX-I and PrTX-I and phospholipase A2 (PLA2s) inhibitor 12- methoxy-4-methyl-voachalotine (MMV) of Tabernamontana catharinensis and rosmarinic acid (Cv-RA) of Rosmarinus officinalis. For both were used cocrystallization experiments with the toxins and inhibitors. In the future, the experimental three-dimensional structures of these complexes will be obtained through the technique of crystallography. Simultaneously, construction occurred in silico of inhibitors Cv-RA and MMV and attempts of docking between these binders and protein structures. These theoretical data provide important information regarding the nature of interactions between inhibitors, toxins and structural changes induced by the protein molecule inhibitors. Therefore, the acquisition of this information has great value to identification, characterization and development (drug design) of compounds with great potential for biotechnology and drug use. Considering further and more relevant aplications, these compounds could be used to control symptoms in many cases of ophidic poisoning and also in combating of pathological processes (degenerative inflammatory diseases and auto-immune diseases, Alzheimer's disease, schizophrenia, among others) whose causes are related to molecules belonging to the same groups of proteins which are classified bothropstoxin that were studied in this project

l-amino acid oxidase from Bothrops marajoensis causes nephrotoxicity in isolated perfused kidney and cytotoxicity in MDCK renal cells

Renal alterations caused by Bothrops venom and its compounds are studied to understand these effects and provide the best treatment. Previously, we studied the renal effect of the whole venom of Bothrops marajoensis and its phospholipase A2 (PLA2), but these effects could not to be attributed to PLA2. To continue the study, we report in this short communication the effects of l-amino acid oxidase from B. marajoensis venom (LAAOBm) on renal function parameter alterations observed in the same model of isolated perfused kidney, as well as the cytotoxic effect on renal cells. LAAOBm caused a decrease in PP, RVR, UF, GFR, %TNa(+) and %TCl(-), very similar to the effects of whole venom using the same model. We also demonstrated its cytotoxicity in MDCK cells with IC50 of 2.5 μg/mL and late apoptotic involvement demonstrated by flow cytometry assays. In conclusion, we suggested that LAAOBm is a nephrotoxic compound of B. marajoensis venom.

Atividade antiviral de compostos naturais no ciclo replicativo do HCV

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

An evaluation of 3-rhamnosylquertetin, a glycolylated form of quercitin, against the myotoxic and edematogenic effects of sPLA2s from Crotalus durissus terrificus

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Caracterização por espectrometria de massas e investigação das atividades anti-inflamatória e gastroprotetora do extrato etanólico e diterpenos clerodânicos de folhas de Casearia sylvestris Swartz

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Caracterização por espectrometria de massas e investigação das atividades anti-inflamatória e gastroprotetora do extrato etanólico e diterpenos clerodânicos de folhas de Casearia sylvestris Swartz

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Funktion des Rezeptors der sekretorischen Phospholipasen A 2 bei der Signaltransduktion in glomerulären Mesangiumzellen und entzündlichen Erkrankungen der Niere

Die sekretorischen Phospholipasen A2 (sPLA2) sind Enzyme, welche die Hydrolyse der Esterbindung an der sn-2-Position von Phospholipiden katalysieren, wodurch freie Fettsäuren, welche als Vorläufermolekül von Eicosanoiden dienen, freiwerden. Außerdem wurde gezeigt, dass sPLA2s auch unabhängig von ihrer katalytischen Aktivität durch die Bindung an einen spezifischen sPLA2-M-Typ-Rezeptor (MTR) intrazelluläre Signalwege, wie z.B. die Induktion von proinflammatorischen Genen, aktivieren können. Deshalb wurden in dieser Arbeit weiterführende Studien zur Aufklärung der Lokalisation und der Signaltransduktion der sPLA2s sowie die Bedeutung des MTR durchgeführt. Als Zellmodell für in-vitro-Studien wurden glomeruläre Mesangiumzellen verwendet, da diese Zellen eine zentrale Rolle bei entzündlichen Nierenerkrankungen, wie z.B. der Glomerulonephritis spielen. Durch Isolierung von Mesangiumzellen aus MTR-knockout-Mäusen (C57BL/6) sollten potentielle Unterschiede in der MTR-vermittelten Signaltransduktion im Vergleich zu Mesangiumzellen isoliert aus (C57BL/6) Wildtyp-Mäusen herausgearbeitet werden. Die Untersuchungen dieser Arbeit zeigen, dass verschiedene sPLA2-Enzyme in Maus-Mesangiumzellen exprimiert werden und diese an der konstitutiven Biosynthese von Prostaglandinen beteiligt sind. Der spezifische M-Typ-Rezeptor wird in diesen Zellen im Gegensatz zu Ratten-Mesangiumzellen weder unter physiologischen noch unter proinflammatorischen Bedingungen exprimiert und spielt daher vermutlich keine Rolle bei der Signaltransduktion durch sPLA2s.

[Glomerulonephritis and vasculitis as causes of arterial hypertension]

The various types of glomerulonephritis, including many forms of vasculitis, are responsible for about 15% of cases of end-stage renal disease (ESRD). Arterial hypertension represents a frequent finding in patients suffering from glomerulonephritis or vasculitis and hypertension also serves as an indicator for these severe types of diseases. In addition, there are symptoms and signs like hematuria, proteinuria and renal failure. Especially, rapidly progressive glomerulonephritis (RPGN) constitutes a medical emergency and must not be missed by treating physicians. This disease can either occur limited to the kidneys or in the context of a systemic inflammatory disorder, like a vasculitis. If left untreated, RPGN can lead to a necrotizing destruction of glomeruli causing irreversible kidney damage within several months or even weeks. With respect to the immunologically caused vasculitis, there are - depending upon the severity and type of organ involved - many clinical warning signs to be recognized, such as arterial hypertension, hemoptysis, arthalgias, muscle pain, palpable purpura, hematuria, proteinuria and renal failure. In addition, constitutional signs, such as fever and loss of body weight may occur concurrently. Investigations of glomerulonephritis or vasculitis must contain a careful and complete examination of family history and medications used by the respective patient. Thereafter, a thorough clinical examination must follow, including skin, joints and measurement of arterial blood pressure. In addition, a spectrum of laboratory analyses is required in blood, such as full blood screen, erythrocyte sedimentation rate, CRP, creatinine, urea and glucose, and in urine, including urinalysis looking for hematuria, red cell casts and proteinuria. Importantly, proteinuria needs to be quantified by the utilization of a random urine sample. Proteinuria > 3g/d is diagnostic for a glomerular damage. These basic tests are usually followed by more specialized analyses, such as a screening for infections, including search for HIV, hepatitis B or C and various bacteria, and for systemic inflammatory diseases, including tests for antibodies, such as ANA, anti-dsDNA, ANCA, anti-GBM and anti-CCP. In cases of membranous nephropathy, antibodies against phospholipase-A2-receptor need to be looked for. Depending upon the given clinical circumstances and the type of disease, a reasonable tumor screening must be performed, especially in cases of membranous and minimal-change nephropathy. Finally, radiological examinations will complete the initial work-up. In most cases, at least an ultrasound of the kidney is mandatory. Thereafter, in most cases a renal biopsy is required to establish a firm diagnosis to define all treatment options and their chance of success. The elimination of a specific cause for a given glomerulonephritis or vasculitis, such as an infection, a malignancy or a drug-related side-effect, remains the key principle in the management of these diseases. ACE-inhibitors, angiotensin receptor-blockers, aldosteron antagonists and renin-inhibitors remain the mainstay in the therapy of arterial hypertension with proteinuria. Only in cases of persistently high proteinuria, ACE-inhibitors and angiotensin receptor blockers can be prescribed in combination. Certain types of glomerulonephritis and essentially all forms of vasculitis require some form of more specific anti-inflammatory therapy. Respective immunosuppressive drug regimens contain traditionally medications, such as glucocorticoids (e. g. prednisone), cyclosporine A, mycophenolate mofetil, cyclophosphamide, and azathioprine. With respect to more severe forms of glomerulonephritis and vasculitis, the antibody rituximab represents a new and less toxic alternative to cyclophosphamide. Finally, in certain special cases, like Goodpasture's syndrome or severe ANCA-positive vasculitis, a plasma exchange will be useful and even required.